Díaz AM, Meléndez V, López C, Sauceda-Acosta D, Álvarez-C DR, Paredes-Bonilla R

Language: Spanish
References: 15
Page: 77-81
PDF size: 1176.92 Kb.

ABSTRACT

Scleroderma is an autoimmune disease of the connective tissue. It is subdivided into systemic and localized scleroderma. Disabling panesclerotic morphea of childhood or panesclerosing scleroderma (PS) is a rare and severe variant of localized scleroderma, usually with a poor prognosis. The treatment of advanced disease remains a challenge for clinicians. The use of biological therapy is controversial and remains in experimental phases. Hereinafter is a case of an 11-year-old patient who underwent rituximab therapy to improve his life quality.

REFERENCES

1. Vasquez-Canizares N, Li SC. Juvenile localized scleroderma: updates and differences from adult-onset disease. Rheum Dis Clin North Am. 2021; 47 (4): 737-755.

2. Ayala-Servin N, Duré-Martinez MA, Urizar-González CA, González M, Contreras CR. Esclerodermia cutánea localizada (Morfea): reporte de caso. Med Clín Soc. 2021; 5 (2): 100-105.

3. Romero DB, Zegpi TMS, Castillo AC, González BS, Torres FS. Morfea en niños: Revisión bibliográfica y puesta al día. Rev Chil Pediatr. 2004; 75 (2): 166-172.

4. Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology. 2006; 45 (5): 614-620.

5. Khamaganova I. Localized scleroderma: predisposing and triggering factors. Open Dermatol J. 2017; 11 (1): 1-11.

6. Velasco-González MV, Paredes MCL, Sánchez M, de Querol S, Esteban SR, Sánchez-Sánchez E et al. Serie: Protocolos de la AEP Comité científico de la Sociedad Española de Reumatología Pediátrica: Serie: Protocolos AEP. Disponible en: www.aeped.es/protocolos/

7. Prasad S, Zhu JL, Schollaert-Fitch K, Torok KS, Jacobe HT. An evaluation of the performance of current morphea subtype classifications. JAMA Dermatol. 2021; 157 (4): 399.

8. Strickler A, Gallo S, Jaramillo P, de Toro G. Morfea o esclerodermia localizada juvenil, caso clínico. Rev Chil Pediatr. 2016; 87 (4): 279-283.

9. Birdi N, Laxer RM, Thorner P, Fritzler MJ, Silverman ED. Localized scleroderma progressing to systemic disease. Case report and review of the literature. Arthritis Rheum. 1993; 36 (3): 410-415.

10. Vierra E, Cunningham BB. Morphea and localized scleroderma in children. Semin Cutan Med Surg. 1999; 18 (3): 210-225.

11. Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology. 2009; 48 (11): 1410-1413.

12. Zulian F, Tirelli F. Treatment in juvenile scleroderma. Curr Rheumatol Rep. 2020; 22 (8): 45.

13. Danés I, Agustí A, Vallano A, Ferrer A, López A, Cortés-Hernández J et al. Available evidence and outcome of off-label use of rituximab in clinical practice. Eur J Clin Pharmacol. 2013; 69 (9): 1689-1699.

14. Rafiq N, Wood M, Leone V. Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part two: Athens, Greece. Pediatr Rheumatol Online J. 2017; 15 (Suppl 2): 65.

15. Daoussis D, Liossis SNC, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 2010; 49 (2): 271-280.